Recent Articles

Gratitude enhances health, brings happiness — and may even lengthen lives

Respiratory health harms often follow flooding: Taking these steps can help

Could tea tree oil help treat acne or athlete’s foot?

Hemoglobin A1c (HbA1c): What to know if you have diabetes or prediabetes or are at risk for these conditions

What could be causing your blurry vision?

Avocado nutrition: Health benefits and easy recipes

Swimming lessons save lives: What parents should know

Preventing and treating iliotibial (IT) band syndrome: Tips for pain-free movement

Wildfires: How to cope when smoke affects air quality and health

What can magnesium do for you and how much do you need?

Adam S. Cheifetz, MD

Contributor

Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.

His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.